Novato-based biopharmaceutical company Ultragenyx Pharmaceutical Inc. is dedicated to developing and distributing new products to treat rare and ultra-rare genetic diseases around the world. Its biologic products, such as Crysvita for X-linked hypophosphatemia and other diseases, Mepsevii for Mucopolysaccharidosis VII, Dojolvi for long-chain fatty acid oxidation disorders, and Evkeeza for homozygous familial hypercholesterolemia, have been well-received. Additionally, the company is working on several product candidates, including DTX401 for glycogen storage disease type Ia, DTX301 for ornithine transcarbamylase, UX143 for osteogenesis imperfecta, GTX-102 for Angelman syndrome, UX111 for Sanfilippo syndrome type A, UX701 for Wilson disease, and UX053 for glycogen storage disease type III. Ultragenyx has partnered with several companies and organizations, such as Kyowa Kirin, Baylor Research Institute, and Regeneron, to further advance its research and development efforts.